Answers are grounded in this paper and cite their sources.
// Congqi Dai 1, * , Fengjuan Lin 1, * , Ruixuan Geng 1 , Xiaoxiao Ge 1 , Wenbo Tang 1 , Jinjia Chang 1 , Zheng Wu 1 , Xinyang Liu 1 , Ying Lin 1 , Zhe Zhang 1 , Jin Li 1, 2 1 Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China 2 Department of Oncology, Tongji University Tianyou Hospital, Shanghai, China * These authors have contributed equally to this work Correspondence to: Jin Li, e-mail: tianyoulijin@163.com Keywords: PD-L1/PD-1, CIK, NKG2D, immunotherapy, gastrointestinal tumor Received: October 21, 2015 Accepted: January 24, 2016 Published: February 08, 2016 ABSTRACT Cytokine-induced killer (CIK) cells represent a realistic approach in cancer immunotherapy with confirmed survival benefits in the context of metastatic solid tumors. However, therapeutic effects are limited to a fraction of patients. In this study, immune-resistance elements and ideal combination therapies were explored. Initially, phenotypic analysis was performed to document CD3, CD56, NKG2D, DNAM-1, PD-L1, PD-1, CTLA-4, TIM-3, 2B4, and LAG-3 on CIK cells. Upon engagement of CIK cells with the tumor cells, expression of PD-1 on CIK cells and PD-L1 on both cells were up-regulated. Over-expression of PD-L1 levels on tumor cells via lentiviral transduction inhibited tumoricidal activity of CIK cells, and neutralizing of PD-L1/PD-1 signaling axis could enhance their tumor-killing effect. Conversely, blockade of NKG2D, a major activating receptor of CIK cells, largely caused dysfunction of CIK cells. Functional study showed an increase of NKG2D levels along with PD-L1/PD-1 blockade in the presence of other immune effector molecule secretion. Additionally, combined therapy of CIK infusion and PD-L1/PD-1 blockade caused a delay of in vivo tumor growth and exhibited a survival advantage over untreated mice. These results provide a preclinical proof-of-concept for simultaneous PD-L1/PD-1 pathways blockade along with CIK infusion as a novel immunotherapy for unresectable cancers.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: